[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR092031A1 - Inhibidores del canal de potasio medular externo renal - Google Patents

Inhibidores del canal de potasio medular externo renal

Info

Publication number
AR092031A1
AR092031A1 ARP130102534A ARP130102534A AR092031A1 AR 092031 A1 AR092031 A1 AR 092031A1 AR P130102534 A ARP130102534 A AR P130102534A AR P130102534 A ARP130102534 A AR P130102534A AR 092031 A1 AR092031 A1 AR 092031A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
bond
cycloalkyl
halo
Prior art date
Application number
ARP130102534A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2012/079184 external-priority patent/WO2014015495A1/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR092031A1 publication Critical patent/AR092031A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Son inhibidores del canal de ROMK (Kir1.1). Los compuestos se pueden usar como agentes diuréticos y/o natriuréticos y para la terapia y la profilaxis de afecciones médicas que incluyen enfermedades cardiovasculares tales como hipertensión, insuficiencia cardíaca y afecciones asociadas con excesiva retención de sal y agua. ROMK (Kir1.1) canal Kir1.1 de Potasio Medular Externo Renal. Reivindicación 1: Un compuesto que tiene la fórmula estructural (1) o una sal farmacéuticamente aceptable del mismo en la que: R¹ es -H, halo, -OH o -O-alquilo C₁₋₃; m es un número entero seleccionado entre cero (R³ᵇ está ausente) y 1 (R³ᵇ está presente); n es un número entero seleccionado entre 1 ó 2; R² está seleccionado independientemente en cada aparición entre -H, =O (oxo), -OH, alquilo C₁₋₃ o -O-alquilo C₁₋₃, con la condición de que cuando n es 2, entonces al menos un R² es -H; R³ᵃ es -H, =O, cicloalquilo C₃₋₄ o alquilo C₁₋₃ opcionalmente sustituido con -OCH₃ o 1 a 3 de -F, con la condición de que sólo uno de R² o R³ᵃ pueden ser =O; R³ᵇ es -H o alquilo C₁₋₃, o R³ᵇ está ausente cuando R³ᵃ es =O ó cuando el enlace discontinuo es un doble enlace o un enlace aromático; o R³ᵃ y R³ᵇ están unidos junto con el carbono al que ambos están unidos para formar ciclopropilo o ciclobutilo; o cuando n es 1, R² y R³ᵃ pueden estar unidos junto con los carbonos a los que cada uno está unido para formar (i) un anillo de fenilo que está condensado con el anillo de pirrolidina, y m es cero, o (ii) un anillo de ciclopropilo condensado con el anillo de pirrolidina, y m es 1; R⁴ es -H o =O; R⁵ es (a) -H, (b) halo, (c) -alquilo C₁₋₃ opcionalmente sustituido con -O-alquilo C₁₋₃, (d) -cicloalquilo C₃₋₆ o (e) heterociclo opcionalmente sustituido con -alquilo C₁₋₃ o halo; R⁶ es -H o alquilo C₁₋₃; R⁷ᵃ es -H o alquilo C₁₋₃ opcionalmente sustituido con -OH, -OCH₃ o 1 a 3 de -F; R⁷ᵇ es -H o -alquilo C₁₋₃; o R⁷ᵃ y R⁷ᵇ están unido junto con el carbono al que ambos están unidos para formar -cicloalquilo C₃₋₄; R⁸ es -H, halo, o -alquilo C₁₋₃; R⁹ es -H, -F, -OH, -O-alquilo C₁₋₃, -CH₂OH, -NH-R¹³ o un resto de fórmula (2); R¹⁰ es -H, halo, -CN, cicloalquilo C₃₋₄, o alquilo C₁₋₃ opcionalmente sustituido con 1 a 3 de -F; o R⁹ es -O- y está unido junto con R¹⁰ para representar -CH₂-CH₂-O-; R¹¹ es -H, -CH₂OH, -CH₂OCH₃, o alquilo C₁₋₃ opcionalmente sustituido con 1 a 3 de -F; R¹² es -H, -CH₂OH, -CH₂OCH₃, o alquilo C₁₋₃ opcionalmente sustituido con 1 a 3 de -F; o R¹¹ y R¹² están unidos entre sí para representar -CH₂-CH₂-, -CH₂-N(CH₃)-CH₂- o -CH₂OCH₂-; R¹³ es -H, -(CH₂)₀₋₂-cicloalquilo C₃₋₆, -(CH₂)₁₋₂-O-cicloalquilo C₃₋₆, -(CH₂)₁₋₂-O-alquilo C₁₋₃, -(CH₂)₁₋₂-CN, -C(O)O-alquilo C₁₋₃, -SO₂CH₃ o alquilo C₁₋₃ opcionalmente sustituido con uno a tres de -F; y el enlace discontinuo (- - -) representa un enlace sencillo, doble o aromático, con la condición de que (A) cuando n es 2, entonces el enlace discontinuo es un enlace sencillo y m es 1; y (B) cuando n es 1 y (i) m es 1 (que incluye pero no se limita a compuestos en los que R² y R³ᵃ están unidos para representar ciclopropilo condensado con el anillo de pirrolidina), o (ii) R³ᵃ es =O y m es cero, entonces el enlace discontinuo es un enlace sencillo; y (C) cuando n es 1, m es cero, R² no es =O y R³ᵃ no es =O, entonces el enlace discontinuo es (i) un doble enlace, o (ii) un enlace aromático R² y R³ᵃ están unidos entre sí para formar el anillo de fenilo condensado con el anillo de pirrolidina.
ARP130102534A 2012-07-26 2013-07-16 Inhibidores del canal de potasio medular externo renal AR092031A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/079184 WO2014015495A1 (en) 2012-07-26 2012-07-26 Inhibitors of the renal outer medullary potassium channel
US201261691390P 2012-08-21 2012-08-21
US201361759040P 2013-01-31 2013-01-31

Publications (1)

Publication Number Publication Date
AR092031A1 true AR092031A1 (es) 2015-03-18

Family

ID=48916271

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102534A AR092031A1 (es) 2012-07-26 2013-07-16 Inhibidores del canal de potasio medular externo renal

Country Status (14)

Country Link
US (2) US8952166B2 (es)
EP (1) EP2877471B1 (es)
JP (1) JP6166783B2 (es)
KR (1) KR20150036142A (es)
CN (1) CN104540826B (es)
AR (1) AR092031A1 (es)
AU (1) AU2013295722B2 (es)
BR (1) BR112015001419A8 (es)
CA (1) CA2876508A1 (es)
ES (1) ES2606016T3 (es)
MX (1) MX365986B (es)
RU (1) RU2642066C2 (es)
TW (1) TW201410675A (es)
WO (1) WO2014018764A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632465B1 (en) 2010-10-27 2015-12-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9062070B2 (en) 2011-08-19 2015-06-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
TW201317213A (zh) * 2011-09-16 2013-05-01 Merck Sharp & Dohme 腎外髓質鉀通道抑制劑
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999991B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066717A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013090271A1 (en) 2011-12-16 2013-06-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9777002B2 (en) 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014099633A2 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014126944A2 (en) 2013-02-18 2014-08-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014150132A1 (en) * 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015103756A1 (en) * 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN106488912A (zh) * 2014-07-14 2017-03-08 默沙东公司 肾外髓质钾通道的抑制剂
WO2016008064A1 (en) * 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
EP3207030A4 (en) * 2014-10-14 2018-06-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065582A1 (en) * 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US20170275292A1 (en) * 2014-10-31 2017-09-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065602A1 (en) * 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2016065603A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR20170090477A (ko) 2014-12-08 2017-08-07 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피리딘카복스아미드 유도체, 그의 제조 방법 및 그의 약학적 용도
EP3250204B1 (en) * 2015-01-29 2019-10-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
JP2019510006A (ja) 2016-02-25 2019-04-11 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
JP6971999B2 (ja) 2016-02-25 2021-11-24 エースニューロン・ソシエテ・アノニム ピペラジン誘導体の酸付加塩
WO2017184662A1 (en) 2016-04-20 2017-10-26 Bristol-Myers Squibb Company Substituted bicyclic heterocyclic compounds
CA3024727A1 (en) * 2016-06-07 2017-12-14 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
CN106432214B (zh) * 2016-08-09 2019-05-07 成都拿盛科技有限公司 一种制备romk通道抑制剂中间体的方法
SG11201903871TA (en) 2016-11-03 2019-05-30 Bristol Myers Squibb Co Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
CN110678463B (zh) 2017-06-01 2023-06-06 百时美施贵宝公司 经取代的含氮化合物
CN107569495A (zh) * 2017-08-10 2018-01-12 新疆医科大学 依普利酮对慢性心力衰竭患者辅助性t细胞活化/增殖的抑制作用
WO2019109935A1 (zh) * 2017-12-06 2019-06-13 江苏恒瑞医药股份有限公司 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法
CN109879863B (zh) * 2017-12-06 2020-10-20 江苏恒瑞医药股份有限公司 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法
JP7210599B2 (ja) * 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
US11731972B2 (en) * 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
CN110669031B (zh) * 2019-11-26 2021-04-16 青岛海洋生物医药研究院股份有限公司 天然产物异猴头菌酮j的全合成方法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2988551A (en) 1954-07-30 1961-06-13 Union Chimique Belge Sa Piperazine derivatives
GB949088A (en) 1961-06-26 1964-02-12 Lepetit Spa Diazabicyclo-octane derivatives
US3435002A (en) 1967-05-15 1969-03-25 Gen Electric Polyamide acid resins and polyimides therefrom
GB1575310A (en) 1976-11-16 1980-09-17 Anphar Sa Piperidine derivatives
FR2522325B1 (fr) 1982-02-26 1985-08-09 Delalande Sa Nouveaux derives aryliques de la piperazine, de l'homopiperazine et de n,n'-dialkyl diamino-1,2 ethane, leur procede de preparation et leur application en therapeutique
NL8202636A (nl) 1982-06-29 1984-01-16 Gist Brocades Nv Piperazinederivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten die deze verbindingen bevatten.
DE3471486D1 (de) 1983-08-15 1988-06-30 Ciba Geigy Ag Photocurable compositions
US5145885A (en) 1983-08-15 1992-09-08 Ciba-Geigy Corporation Photopolymerizable compositions containing aminoaryl ketone photoinitiators
US4579863A (en) 1983-12-06 1986-04-01 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4661607A (en) 1984-09-21 1987-04-28 Chugai Seiyaku Kabushiki Kaisha Furoxanthone derivatives useful as diuretics
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
GB8603120D0 (en) 1986-02-07 1986-03-12 Pfizer Ltd Anti-dysrhythmia agents
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
FR2673182A1 (fr) 1991-02-22 1992-08-28 Univ Caen Piperazines n,n'-disubstituees, leur procede de preparation et leur application en therapeutique.
DE69426157T2 (de) 1993-07-28 2001-05-17 Santen Pharmaceutical Co., Ltd 1,4-di(phenylalkyl)piperazinderivate
US5614526A (en) 1995-06-09 1997-03-25 Hoffmann-La Roche Inc. Use of phenoxy-piperzine derivatives
ATE209192T1 (de) 1996-05-20 2001-12-15 Teijin Ltd Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
JPH10203986A (ja) 1997-01-22 1998-08-04 Mitsubishi Chem Corp 眼疾患用薬剤
WO2000051611A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1094063A1 (en) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazoles as Bax-modulators
US6787543B2 (en) 2000-06-29 2004-09-07 Fujisawa Pharmaceutical Co., Ltd. Benzhydryl derivatives
US6352158B1 (en) 2000-07-06 2002-03-05 Warner Lambert Company Unit dose blister package with keyhole assisted opening feature
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
CN1172919C (zh) 2002-06-03 2004-10-27 上海医药工业研究院 芳烷醇哌嗪衍生物及其在制备抗抑郁症药物中的应用
GB0220214D0 (en) 2002-08-30 2002-10-09 Novo Pharmaceuticals De Ltd Compounds and their use
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
AU2003275632A1 (en) 2002-10-25 2004-05-13 Mitsubishi Pharma Corporation N-oxide compounds
US7831263B2 (en) 2002-11-08 2010-11-09 Qualcomm Incorporated Apparatus and method for determining the location of a repeater
JPWO2004046110A1 (ja) 2002-11-15 2006-03-16 アステラス製薬株式会社 メラニン凝集ホルモン受容体拮抗剤
PL377864A1 (pl) 2003-04-03 2006-02-20 Merck Patent Gmbh Pochodne 1-N-(fenylo)-2-N-(fenylo)pirazolidyno-1,2-dikarboksyamidowe jako inhibitory czynnika koagulacyjnego Xa do leczenia zakrzepic
DE10329457A1 (de) 2003-04-03 2005-01-20 Merck Patent Gmbh Ethinylprolinderivate
EP1720844B1 (de) 2003-04-03 2009-04-29 MERCK PATENT GmbH Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
AU2004246766B2 (en) 2003-06-18 2009-09-17 Merck Patent Gmbh Pyrrolidin-1, 2- dicarboxylic acid- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative as inhibitors of coagulation factor Xa and VIIa for the treatment of thrombosis
EP1653960A4 (en) 2003-08-13 2008-11-26 Amgen Inc MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
ES2295963T3 (es) * 2004-01-08 2008-04-16 F. Hoffmann-La Roche Ag Derivados diaza-espiropiperidina como inhibidores del transportador 1 de glicina y transportador 2 de glicina.
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
DE102004047254A1 (de) 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
WO2006098342A1 (en) 2005-03-16 2006-09-21 Astellas Pharma Inc. Piperazinyl compounds
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
BRPI0616574A2 (pt) 2005-09-27 2009-11-24 Shionogi & Co derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
AU2006331882A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
WO2008147864A2 (en) 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
CA2727780A1 (en) 2008-06-13 2009-12-17 Bionomics Limited Novel potassium channel blockers and uses thereof
US8673920B2 (en) * 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632465B1 (en) 2010-10-27 2015-12-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9062070B2 (en) 2011-08-19 2015-06-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
TW201317213A (zh) 2011-09-16 2013-05-01 Merck Sharp & Dohme 腎外髓質鉀通道抑制劑
US8999991B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066717A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013090271A1 (en) 2011-12-16 2013-06-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Also Published As

Publication number Publication date
TW201410675A (zh) 2014-03-16
AU2013295722A1 (en) 2015-01-15
BR112015001419A2 (pt) 2017-07-04
JP2015523399A (ja) 2015-08-13
MX365986B (es) 2019-06-20
US9206198B2 (en) 2015-12-08
RU2642066C2 (ru) 2018-01-24
US20150099729A1 (en) 2015-04-09
AU2013295722B2 (en) 2017-12-07
JP6166783B2 (ja) 2017-07-19
US20140031349A1 (en) 2014-01-30
CN104540826B (zh) 2018-04-20
MX2015001115A (es) 2015-04-08
WO2014018764A1 (en) 2014-01-30
RU2015106139A (ru) 2016-09-20
KR20150036142A (ko) 2015-04-07
US8952166B2 (en) 2015-02-10
ES2606016T3 (es) 2017-03-17
CN104540826A (zh) 2015-04-22
CA2876508A1 (en) 2014-01-30
EP2877471A1 (en) 2015-06-03
EP2877471B1 (en) 2016-11-02
BR112015001419A8 (pt) 2019-07-30

Similar Documents

Publication Publication Date Title
AR092031A1 (es) Inhibidores del canal de potasio medular externo renal
AR094668A1 (es) Amidas como moduladores de canales de sodio
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR094537A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
AR092959A1 (es) Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR099785A1 (es) Compuestos heteroarilos y su uso como medicamentos
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR099363A1 (es) Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR094263A1 (es) Compuestos moduladores selectivos de proteinquinasas
AR106652A1 (es) Compuestos para tratar la esclerosis lateral amiotrófica
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
PE20210398A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR108906A1 (es) Heterociclos de biarilmetilo
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR092288A1 (es) Ligandos del receptor ep1
AR111301A1 (es) Amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico sustituidas y su compuesto como herbicidas
AR100439A1 (es) Derivados de carboxamida
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
AR102222A1 (es) Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos
AR116905A1 (es) Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor

Legal Events

Date Code Title Description
FB Suspension of granting procedure